Bibliography
1. Brouwer, M. C., McIntyre, P., Prasad, K., & van de Beek, D. (2015). Corticosteroids for acute bacterial meningitis. The Cochrane database of systematic reviews, 2015(9), CD004405
​
2. El Bashir, H., Laundy, M., Booy, R. (2003). Diagnosis and treatment of bacterial meningitis Archives of Disease in Childhood, 88, 615-620.
​
3. Johswich, K. (2017). Innate immune recognition and inflammation in Neisseria meningitidis infection, Pathogens and Disease, 75(2).
​
4. Munguambe, A. M., de Almeida, A., Nhantumbo, A. A., Come, C. E., Zimba, T. F., Paulo Langa, J., de Filippis, I., & Gudo, E. S. (2018). Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis. PloS one, 13(8), e0197390.
​
5. Rouphael, N. G., & Stephens, D. S. (2012). Neisseria meningitidis: biology, microbiology, and epidemiology. Methods in molecular biology (Clifton, N.J.), 799, 1–20.
​
6. Sadeghi, M., Ahmadrajabi, R., Dehesh, T., & Saffari, F. (2018). Prevalence of meningococcal carriage among male university students living in dormitories in Kerman, southeast of Iran. Pathogens and global health, 112(6), 329–333.
​
7. Stephens D. S. (2009). Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis. Vaccine, 27 Suppl 2(Suppl 2), B71–B77.
​
8. Swanson, D. (2015). Meningitis. Pediatr Rev, 36(12), 514–526.
​
9. Uria, M. J., Zhang, Q., Li, Y., Chan, A., Exley, R. M., Gollan, B., Chan, H., Feavers, I., Yarwood, A., Abad, R., Borrow, R., Fleck, R. A., Mulloy, B., Vazquez, J. A., & Tang, C. M. (2008). A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. The Journal of experimental medicine, 205(6), 1423–1434.
​
10. Meyer SA, Kristiansen PA. Household transmission of Neisseria meningitidis in the meningitis belt. The Lancet Global Health. 2016 Dec;4(12):e885–6.
11. Merz AJ, Rifenbery DB, Arvidson CG, So M. Traversal of a Polarized Epithelium by Pathogenic Neisseriae: Facilitation by Type IV Pili and Maintenance of Epithelial Barrier Function. Molecular Medicine. 1996 Nov;2(6):745–54.
12. Kuespert K, Roth A, Hauck CR. Neisseria meningitidis Has Two Independent Modes of Recognizing Its Human Receptor CEACAM1. Ahmed N, editor. PLoS ONE. 2011 Jan 27;6(1):e14609.
13. Rouphael NG, Stephens DS. Neisseria meningitidis: Biology, Microbiology, and Epidemiology. Methods in Molecular Biology [Internet]. 2011 Sep 9 [cited 2021 Oct 29];799:1–20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349422/
14. Schubert-Unkmeir A. Molecular mechanisms involved in the interaction of Neisseria meningitidis with cells of the human blood–cerebrospinal fluid barrier. Pathogens and Disease. 2017 Mar 1;75(2).
15. Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence [Internet]. 2014 Jan 1 [cited 2021 Oct 25];5(1):98–126. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916388/
16. Tan LA, Yu B, Sim FCJ, Kishore U, Sim RB. Complement activation by phospholipids: the interplay of factor H and C1q. Protein & Cell. 2010 Nov;1(11):1033–49.
17. Kugelberg E, Gollan B, Tang CM. Mechanisms in Neisseria meningitidis for resistance against complement-mediated killing. Vaccine. 2008 Dec;26:I34–9.
18. Plant L, Sundqvist J, Zughaier S, Lövkvist L, Stephens DS, Jonsson A-B. Lipooligosaccharide Structure Contributes to Multiple Steps in the Virulence of Neisseria meningitidis. Infection and Immunity [Internet]. 2006 Feb 1 [cited 2021 Dec 26];74(2):1360–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1360357/
19. Hsieh SA, Allen PM. Immunomodulatory Roles of Polysaccharide Capsules in the Intestine. Frontiers in Immunology [Internet]. 2020 Apr 15 [cited 2021 Oct 26];11:690. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174666/
20. Johswich K. Innate immune recognition and inflammation in Neisseria meningitidis infection. Pathogens and Disease. 2017 Mar 1;75(2).
21. Coureuil M, Mikaty G, Miller F, Lécuyer H, Bernard C, Bourdoulous S, et al. Meningococcal Type IV Pili Recruit the Polarity Complex to Cross the Brain Endothelium. Science. 2009 Jun 11;325(5936):83–7.
22. Maïssa N, Covarelli V, Janel S, Durel B, Simpson N, Bernard SC, et al. Strength of Neisseria meningitidis binding to endothelial cells requires highly-ordered CD147/β2-adrenoceptor clusters assembled by alpha-actinin-4. Nature Communications [Internet]. 2017 Jun 1 [cited 2021 Oct 27];8:15764. Available from: https://pubmed.ncbi.nlm.nih.gov/28569760/
23. Virji M. Pathogenic neisseriae: surface modulation, pathogenesis and infection control. Nature Reviews Microbiology [Internet]. 2009 Apr [cited 2021 Nov 15];7(4):274–86. Available from: https://www.nature.com/articles/nrmicro2097
24. F Verheul A. TABLE 2 . Virulence factors of N. meningitidis [Internet]. ResearchGate. 1993 [cited 2021 Nov 15]. Available from: https://www.researchgate.net/figure/Virulence-factors-of-N-meningitidis_tbl2_14735718
25. Soriani M. Unraveling Neisseria meningitidis pathogenesis: from functional genomics to experimental models. F1000Research [Internet]. 2017 Jul 26 [cited 2021 Dec 23];6:1228. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531161/
26. Hasudungan A. (Bacterial) Meningitis Pathophysiology [Internet]. YouTube. 2017 [cited 2021 Dec 23]. Available from: https://www.youtube.com/watch?v=xQC6L8M6XfU
​
27. Harrison, L., Trotter, C. & Ramasay, M., 2009. Global epidemiology of meningococcal disease. Vaccine, Volume 27, p. B51–B63.
​
28. WHO, n.d. World Health Organisation: Meningitis Overview. [Online]Available at: https://www.who.int/health-topics/meningitis#tab=tab_1[Accessed 7 November 2021].
​
29. Davison, K. & Ramsay, M., 2003. The epidemiology of acute meningitis in children in England and Wales. Archives of Disease in Childhood, 88(8), p. 662–664.
​
30. Gabutti, G. & Stefanati, A. a. K. P., 2015. Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage. Journal of preventive medicine and hygiene, 56(3), pp. E116-20.
​
31. Zunt, J. e. a., 2018. Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(12), p. 1061–1082.
​
32. WHO, 2021. World Health Organisation: Meningitis. [Online]
Available at: https://www.who.int/news-room/fact-sheets/detail/meningitis
[Accessed 7 November 2021].
​
33. Linder, K. a. M. P., 2019. Meningococcal Meningitis. JAMA, 321(10), p. 1014.
​
34. ECDC, 2021. European Centre for Disease Prevention and Control: Factsheet about meningococcal disease. [Online]
Available at: https://www.ecdc.europa.eu/en/meningococcal-disease/factsheet
[Accessed 7 November 2021].
​
35. Stephens, D. S., Greenwood, B. & Brandtzaeg, P., 2007. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. The Lancet, 369(9580), pp. 2196-2210.
​
36. ECDC, 2017. European Centre for Disease Prevention and Control. Invasive Meningococcal Disease: Annual Epidemiological Report for 2015.
​
37. Mohammed, I. & Iliyasu, G. a. H. A., 2017. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.. Pathogens and Global Health, 111(1), p. 1–6.
​
38. Soeters, H. M. et al., 2019. Bacterial Meningitis Epidemiology in Five Countries in the Meningitis Belt of Sub-Saharan Africa, 2015–2017. The Journal of Infectious Diseases, 220(4), pp. S165-S174.
​
39. Mazamay, S. e. a., 2021. An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics “outside-the-belt.”. BMC Infectious Diseases, Volume 21, p. 1027.
​
40. Vasudeva Shikha S, MBBS Assistant Professor of Internal Medicine, Virginia Tech Carilion School of Medicine; Nov 16, 2021; Meningitis
​
41. Nadine G. Rouphael and David S. Stephens, 2015 Mar 4; Neisseria meningitidis: Biology, Microbiology, and Epidemiology
​
42. Runde; Tyler J. 2021; Fatima Anjum; John W. Hafner; Illinois College of Medicine; Bacterial Meningitis
​
43. Diederik van de Beek 1, Jan de Gans, Lodewijk Spanjaard, Martijn Weisfelt, Johannes B Reitsma, Marinus Vermeulen; 004 Oct 28;351(18):1849-59. doi: 10.1056/NEJMoa040845; Clinical features and prognostic factors in adults with bacterial meningitis
44. Hoffmann O., Keilwerth N., Bille M.B., Reuter U., Angstwurm K., Schumann R.R.et al. (2002) Triptans reduce the inflammatory response in bacterial meningitis. J Cereb Blood Flow Metab 22:988–996
​
45. Bashir H El, M Laundy, and R Booy; 2003 Jul; Academic Department of Child Health, Queen Mary School of Medicine and Dentistry at Barts and The London, 88(7): 615–620; Diagnosis and treatment of bacterial meningitis
​
46. Rappuoli Rino NORD gratefully acknowledges, PhD, Global Head of Vaccines Research, Novartis Vaccines and Diagnostics, Siena, Italy, for assistance in the preparation of this report, Meningococcal Meningitis
​
47. Kandola Aaron; 2020; The Journal of Medical News Today; What is a complete blood count?
​
48. Li Shan,corresponding author. Ivy P. Nguyen, and Kyle Urbanczyk; 2020 Dec; 10(12): 2227–2259.doi: 10.21037/qims-20-886; Common infectious diseases of the central nervous system—clinical features and imaging characteristics
​
49. Ragunathan L, Ramsay M, Borrow R, et al. Clinical features, laboratory findings and management of meningococcal meningitis in England and Wales: report of a 1997 survey. Meningococcal meningitis: 1997 survey report. J Infect 2000;40: 74–9.
​
50. Karki Bhesh R.; Yub Raj Sedhai; Syed Rizwan A. Bokhari; July 30, 2021; Waterhouse-Friderichsen Syndrome
​
51. Goel Anju, MD board-certified in internal medicine, September 10, 2021; Symptoms of Meningitis
​
52. Nash Anthony A., Robert G. Dalziel, and J. Ross Fitzgerald; 2015: 171–231.Published online 2015 Feb 6. doi: 10.1016/B978-0-12-397188-3.00008-1; Mechanisms of Cell and Tissue Damage
​
53. Runde; Tyler J. 2021; Fatima Anjum; John W. Hafner; Illinois College of Medicine; Bacterial Meningitis
​
54. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006;367:397–403.
​
55. Greeff SC, Melker HE, Schouls LM, et al. Pre-admission clinical course of menin- gococcal disease and opportunities for the earlier start of appropriate interven- tion: a prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis 2008;27:985–92.)
​
56. Nixon Nguyen; Derrick Ashong. October 12, 2021; Neisseria Meningitidis
​
57. Barrell Amanda on January 27, 2021; Medical News Today; Causes for a non-blanching rash in adults and children
​
58. Carter Katherine; March 2019; Meningitis Research Foundation; “What is the 'meningitis rash'?”
​
59. Wan Cordia, MD Adult Neurologist, Kaiser Permanente Hawaii, Kaiser Permanente Southern California; Jul 17, 2018, Chief Editor: Niranjan N Singh, MBBS, MD, Viral Meningitis Workup
​
60. Santistevan Jamie, MD (ED Quality and Administrative Fellow, University of Wisconsin, Edited by: Alex Koyfman, MD (@EMHighAK, EM Attending Physician, UT Southwestern Medical Center / Parkland Memorial Hospital); JUL 18TH, 2016; What’s that Rash? An approach to dangerous rashes based on morphology.
​
61. Biggers Alana Medically reviewed, M.D., MPH — Written by Markus MacGill on November 16, 2018; What are the causes of a low platelet count?
​
62. Hoffmann O., Keilwerth N., Bille M.B., Reuter U., Angstwurm K., Schumann R.R.et al. (2002) Triptans reduce the inflammatory response in bacterial meningitis. J Cereb Blood Flow Metab 22:988–996
​
63. Van de Beek D, de Gans J, Spanjaard L, et al. Clinical features, and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:1849–59.
​
64. Griffiths, M., McGill, F. and Solomon, T., 2018. Management of acute meningitis. Clinical Medicine, 18(2), pp.164-169.
​
65. Brouwer, M., McIntyre, P., Prasad, K. and van de Beek, D., 2015. Corticosteroids for acute bacterial meningitis. Cochrane Database of Systematic Reviews, (9).
​
66. Murray, P., Rosenthal, K. and Pfaller, M., 2015. Medical microbiology. 8th ed. Elsevier, p.235.
​
67. Brooks, G., Carroll, K., Butel, J. and Morse, S., 2007. Jawetz, Melnick & Adelberg's Medical Microbiology. 24th ed. McGraw-Hill Medical, pp.176, 302, 303.
​
68. Willerton, L., Lucidarme, J., Walker, A., Lekshmi, A., Clark, S., Walsh, L., Bai, X., Lee-Jones, L. and Borrow, R., 2021. Antibiotic resistance among invasive Neisseria meningitidis isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). PLOS ONE, 16(11), pp.1-19.
​
69. NICE Excellence., 2021. BENZYLPENICILLIN SODIUM | Drug | BNF content published by NICE. [online] Bnf.nice.org.uk. Available at: <https://bnf.nice.org.uk/drug/benzylpenicillin-sodium.html> [Accessed 5 November 2021].
​
70. NICE Excellence., 2021. CEFOTAXIME | Drug | BNF content published by NICE. [online] Bnf.nice.org.uk. Available at: <https://bnf.nice.org.uk/drug/cefotaxime.html> [Accessed 5 November 2021].
​
71. NICE Excellence., 2021. CEFTRIAXONE | Drug | BNF content published by NICE. [online] Bnf.nice.org.uk. Available at: <https://bnf.nice.org.uk/drug/ceftriaxone.html#indicationsAndDoses> [Accessed 5 November 2021].
​
72. Rouphael, N. and Stephens, D., 2012. Neisseria meningitidis: Biology, Microbiology, and Epidemiology. Methods in Molecular Biology, 799, pp.1-20.